サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511933

基底細胞がん治療の市場規模、シェア、動向分析レポート：治療タイプ別、地域別、セグメント別予測、2024年～2030年

Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 158 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
基底細胞がん治療の市場規模、シェア、動向分析レポート：治療タイプ別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年06月20日
発行: Grand View Research
ページ情報: 英文 158 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

基底細胞がん治療市場の成長と動向：

Grand View Research社の最新レポートによると、世界の基底細胞がん治療市場規模は2030年までに59億3,000万米ドルに達し、2024年から2030年までのCAGRは10.44％で成長すると予測されています。

同市場は主に、基底細胞がんの有病率の増加と老年人口の増加が牽引しています。欧州皮膚がん財団の推定によると、基底細胞がん（BCC）の発生率は、欧州では人口10万人当たり年間50～80人、オーストラリアでは人口10万人当たり年間250人が新たに発症し、増加傾向にあります。がん患者数の増加は、主に全人口と老年人口の増加と特定の社会経済的要因に起因しています。

疾患の診断と治療における技術の進歩は、市場成長にプラスの影響を与えると予想されます。先進技術により、皮膚科医は患者をより正確に診断し、基底細胞がんを他の皮膚病変から効果的に鑑別することができます。例えば、2024年に米国FDAは、メラノーマ、単細胞がん（SCC）、基底細胞がん（BCC）を含む皮膚がんを検出するためのAI搭載光分光器DermaSensorを承認しました。この技術は、プライマリ・ケアの臨床医が、生検や専門医による治療を迅速に受ける必要のある患者を特定するのに役立ち、それによって待ち時間の長さや特定の地域における皮膚科医の不足を緩和することができます。このような診断ツールの使用が増えることで、将来的には診断率や治療率が向上し、基底細胞がんの治療に使用される医薬品の需要を牽引すると予想されます。

さらに、老人人口の増加が、手術、放射線治療、局所化学療法、内服薬、ケミカルピーリングなどのBCC治療に対する需要を牽引しています。BCCを発症する主な原因は、紫外線（UV）に繰り返しさらされることです。高齢者は紫外線にさらされる時間が長いため、若年者よりもBCCを発症する確率が高いです。加齢や免疫機能の低下により、紫外線やその他の発がん因子はDNAをより容易に破壊するため、高齢者では皮膚がん、特にBCCのリスクが高まる。2023年にJournal of Geriatric Oncology誌に発表された研究によると、米国では毎年10万人以上のBCC患者が人生の最終年に治療を受けています。従って、高齢者人口の増加が予測期間中の市場成長を促進すると予想されます。

基底細胞がん治療レポート・ハイライト

  • 2023年の市場で最大の収益シェアを占めたのは手術セグメントでした。これは、疾患の罹患率と有病率の増加、および高い安全性と有効性による治療のための手術の高い需要に起因しています。
  • 局所化学療法では、5-フルオロウラシル（5-FU）セグメントが2023年に市場で最大のシェアを占めました。これは、BCC患者を治療するための5-フルオロウラシル（5-FU）の新しいジェネリックバージョンの開発・上市に起因しています。
  • 北米は、高度なヘルスケアインフラ、基底細胞がんの有病率の増加、新製品の研究開発に有利な規制環境などの要因により、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 基底細胞がん治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 基底細胞がん治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 基底細胞がん治療市場：治療タイプの推定・動向分析

  • 世界の基底細胞がん治療市場：治療タイプダッシュボード
  • 世界の基底細胞がん治療市場：治療タイプの変動分析
  • 世界の基底細胞がん治療市場：治療タイプ別、収益別
  • 手術
  • 放射線治療（RT）
  • 病変内注射
  • 局所化学療法
  • 経口薬
  • 静脈内投与薬
  • ケミカルピーリング治療

第5章 基底細胞がん治療市場：治療タイプ別の地域推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 企業/競合の分類
  • 参入企業の概要
  • 財務概要
  • 治療タイプのベンチマーク
  • 企業市場シェア分析、2023年
  • 戦略マッピング
  • 企業プロファイル
    • Bausch Health Companies Inc.
    • Almirall, SA
    • Genentech, Inc.（Subsidiary of F. Hoffmann-La Roche AG）
    • Novartis AG.
    • Regeneron Pharmaceuticals Inc.
    • Dr Reddy's Laboratories.
    • Taro Pharmaceuticals Ltd.
    • Accord Healthcare Limited（Subsidiary of Intas Pharmaceuticals）
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 4 U.S. basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 5 Canada basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 6 Mexico basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 7 Europe basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 9 Germany basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 10 UK basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 11 France basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 12 Italy basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 13 Spain basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 14 Denmark basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 15 Sweden basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 16 Norway basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 19 China basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 20 Japan basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 21 India basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 22 South Korea basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 23 Australia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 24 Thailand basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 25 Latin America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 26 Latin America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 27 Brazil basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 28 Argentina basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 29 MEA basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 30 MEA basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 31 South Africa basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 33 UAE basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 34 Kuwait basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Basal cell carcinoma treatments market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment type segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 PESTLE analysis
  • Fig. 15 Basal cell carcinoma treatment market: Treatment type outlook key takeaways
  • Fig. 16 Basal cell carcinoma treatment market: Treatment type movement analysis
  • Fig. 17 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mohs surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Tumor removal procedures (including skin cancer)
  • Fig. 20 Surgical excision market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Electrodesiccation and Curettage (ED&C) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Radiotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Intralesional injections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Topical chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 5-fluorouracil (5-FU) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Tirbanibulin (Klisyri) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Imiquimod (Zyclara) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Vismodegib (Erivedge) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sonidegib (Odomzo) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Intravenous medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Chemical peeling treatment minimally invasive procedures, 2018 - 2030 (USD Million)
  • Fig. 33 Chemical peeling treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Basal cell carcinoma treatment market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Regulatory framework
  • Fig. 45 Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 UK basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Germany basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 France basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Denmark basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Sweden basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Norway basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Rest of Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Japan pharmaceutical registration
  • Fig. 67 Key country dynamics
  • Fig. 68 China basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Regulatory details: China
  • Fig. 70 Key country dynamics
  • Fig. 71 India basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Registration details: India
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Drug pricing: Australia
  • Fig. 76 Contribution of PBS by disease
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Reimbursement scenario: South Korea
  • Fig. 82 Rest of Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Argentina basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina pharmaceuticals registration details
  • Fig. 89 Argentina pharmaceuticals reimbursement details
  • Fig. 90 Rest of Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Regulatory framework: South Africa
  • Fig. 95 Regulatory framework: South Africa drug registration fees
  • Fig. 96 Key country dynamics
  • Fig. 97 Saudi Arabia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Regulatory framework: Kuwait
  • Fig. 103 Rest of MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Market participant categorization
  • Fig. 105 Heat map analysis
  • Fig. 106 Strategic framework
目次
Product Code: GVR-4-68040-170-1

Basal Cell Carcinoma Treatment Market Growth & Trends:

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights:

  • The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
  • In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Type Outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adverse effects associated with treatment.
      • 3.2.2.2. High cost of treatment
  • 3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
  • 4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
  • 4.4. Surgery
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Mohs Surgery
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Surgical Excision
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Electrodesiccation and Curettage (ED&C)
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Radiotherapy (RT)
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Intralesional Injections
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Topical Chemotherapy
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. 5-fluorouracil (5-FU)
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Tirbanibulin (Klisyri)
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Imiquimod (Zyclara)
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Oral Medications
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Vismodegib (Erivedge)
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Sonidegib (Odomzo)
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Intravenous Medications
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Chemical Peeling Treatment
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. South Korea
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Overview
  • 6.4. Treatment Type Benchmarking
  • 6.5. Company Market Share Analysis, 2023
  • 6.6. Strategy Mapping
  • 6.7. Company Profiles
    • 6.7.1. Bausch Health Companies Inc.
      • 6.7.1.1. Company overview
      • 6.7.1.2. Financial performance
      • 6.7.1.3. Product benchmarking
      • 6.7.1.4. Strategic initiatives
    • 6.7.2. Almirall, S.A.
      • 6.7.2.1. Company overview
      • 6.7.2.2. Financial performance
      • 6.7.2.3. Product benchmarking
      • 6.7.2.4. Strategic initiatives
    • 6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
      • 6.7.3.1. Company overview
      • 6.7.3.2. Financial performance
      • 6.7.3.3. Product benchmarking
      • 6.7.3.4. Strategic initiatives
    • 6.7.4. Novartis AG.
      • 6.7.4.1. Company overview
      • 6.7.4.2. Financial performance
      • 6.7.4.3. Product benchmarking
      • 6.7.4.4. Strategic initiatives
    • 6.7.5. Regeneron Pharmaceuticals Inc.
      • 6.7.5.1. Company overview
      • 6.7.5.2. Financial performance
      • 6.7.5.3. Product benchmarking
      • 6.7.5.4. Strategic initiatives
    • 6.7.6. Dr Reddy's Laboratories.
      • 6.7.6.1. Company overview
      • 6.7.6.2. Financial performance
      • 6.7.6.3. Product benchmarking
      • 6.7.6.4. Strategic initiatives
    • 6.7.7. Taro Pharmaceuticals Ltd.
      • 6.7.7.1. Company overview
      • 6.7.7.2. Financial performance
      • 6.7.7.3. Product benchmarking
      • 6.7.7.4. Strategic initiatives
    • 6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
      • 6.7.8.1. Company overview
      • 6.7.8.2. Financial performance
      • 6.7.8.3. Product benchmarking
      • 6.7.8.4. Strategic initiatives